Plaque Psoriasis
344
27
49
236
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
146 trials with published results (42%)
Research Maturity
236 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
5.5%
19 terminated out of 344 trials
92.5%
+6.0% vs benchmark
45%
155 trials in Phase 3/4
62%
146 of 236 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 236 completed trials
Clinical Trials (344)
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
Modifying PEST for Psoriatic Arthritis Screening
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis